Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists (Drug Safety, (2019), 10.1007/s40264-019-00812-7)

Abstract

In the original publication of this article, the following correction should be noted in Table 1. The drug “Orlistat” was incorrectly changed to “Gastrointestinal lipase inhibitor”. Indeed, the “Pancreas lipase inhibitor” in the column “Primary mechanism of action” should have been replaced with “Gastrointestinal lipase inhibitor”. The original article has been corrected.